Switch tacrolimus timing after liver transplant to Envarsus
Part of Immune system & allergy clinical trials.
This trial looks at whether changing your maintenance anti-rejection medicine from Prograf (usually twice daily) to Envarsus (once daily) can help keep your liver and kidney function stable. It targets people who may be having kidney side effects, symptoms from tacrolimus, or trouble taking a twice-daily medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18) and have had a liver transplant
- Your transplant was more than 12 months ago
- You are currently taking Prograf (tacrolimus) as your usual maintenance medicine, with blood levels in the 5–10 range
- Your liver blood tests and bilirubin are stable (within certain limits) around the start of the study
- Your kidney function is stable (creatinine and eGFR meet study cutoffs) around the start of the study
- No acute rejection episode in the last 6 months, and you have either higher creatinine, bothersome tacrolimus side effects, or trouble sticking to a twice-daily schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
This study compares two long-acting forms of tacrolimus (Envarsus and Advagraf) to see how the body processes them after a kidney transplant. It aims to find the best way to use these medications to prevent organ rejection.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This trial tests a special form of tacrolimus (Envarsus) taken once daily to prevent organ rejection in people who recently received a first lung transplant. The study will follow patients for at least 12 months.
Hear when a new Liver Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.